Cellectis getting $28M for allogeneic CAR T-cell therapy
By Cormac Sheridan
Tuesday, April 1, 2014
Cellectis SA completed a €20.5 (US$28.3 million) million private placement with a syndicate of U.S. investors to use its suite of technologies for engineering T cells and chimeric antigen receptors (CARs) in the development an allogeneic cell therapy based on CAR-transduced T cells.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.